Infection Prevention in the Immunocompromised Traveler Due to Conditions Other Than Transplantation: a Review

Overview

Journal Ther Adv Infect Dis

Publisher Sage Publications

Date 2025 Jan 27

PMID 39866828

Authors

Joseph Sassine

Emily A Siegrist

Rita Wilson Dib

Jose Henao-Cordero

Nelson Ivan Agudelo Higuita

Affiliations

Soon will be listed here.

Abstract

This narrative review explores the risks related to infection in immunocompromised travelers due to conditions other than transplantation, and evaluates the evidence behind current prophylactic strategies, including immunizations, antimicrobials, and non-pharmacological interventions, to prevent various infection and how the current evidence applies to this special patient population, from the perspective of a US-based traveler.

References

Nelson N . Updated Dosing Instructions for Immune Globulin (Human) GamaSTAN S/D for Hepatitis A Virus Prophylaxis. MMWR Morb Mortal Wkly Rep. 2017; 66(36):959-960. PMC: 5657912. DOI: 10.15585/mmwr.mm6636a5. View

. Prevention of invasive group A streptococcal disease among household contacts of case patients and among postpartum and postsurgical patients: recommendations from the Centers for Disease Control and Prevention. Clin Infect Dis. 2002; 35(8):950-9. DOI: 10.1086/342692. View

Sahra S, Villalobos R, Scott B, Bowman D, Sassine J, Salvaggio M . The diagnostic dilemma for atypical presentation of progressive human Mpox. BMC Infect Dis. 2023; 23(1):850. PMC: 10696784. DOI: 10.1186/s12879-023-08852-2. View

Sherrard A, McCarthy A . Travel patterns and health risks for patients infected with HIV. Travel Med Infect Dis. 2009; 7(5):291-5. DOI: 10.1016/j.tmaid.2009.03.006. View

de Vries-Sluijs T, Hansen B, van Doornum G, Kauffmann R, Leyten E, Mudrikova T . A randomized controlled study of accelerated versus standard hepatitis B vaccination in HIV-positive patients. J Infect Dis. 2011; 203(7):984-91. DOI: 10.1093/infdis/jiq137. View

Kemper , Linett , Kane , Deresinski . Frequency of Travel of Adults Infected with HIV. J Travel Med. 1995; 2(2):85-88. DOI: 10.1111/j.1708-8305.1995.tb00632.x. View

Biggs H, Behravesh C, Bradley K, Dahlgren F, Drexler N, Dumler J . Diagnosis and Management of Tickborne Rickettsial Diseases: Rocky Mountain Spotted Fever and Other Spotted Fever Group Rickettsioses, Ehrlichioses, and Anaplasmosis - United States. MMWR Recomm Rep. 2016; 65(2):1-44. DOI: 10.15585/mmwr.rr6502a1. View

Davis J, Ferreira D, Paige E, Gedye C, Boyle M . Infectious Complications of Biological and Small Molecule Targeted Immunomodulatory Therapies. Clin Microbiol Rev. 2020; 33(3). PMC: 7289788. DOI: 10.1128/CMR.00035-19. View

Veit O, Niedrig M, Chapuis-Taillard C, Cavassini M, Mossdorf E, Schmid P . Immunogenicity and safety of yellow fever vaccination for 102 HIV-infected patients. Clin Infect Dis. 2009; 48(5):659-66. DOI: 10.1086/597006. View

10.

Wallace M, Brandt C, Earhart K, Kuter B, Grosso A, Lakkis H . Safety and immunogenicity of an inactivated hepatitis A vaccine among HIV-infected subjects. Clin Infect Dis. 2004; 39(8):1207-13. DOI: 10.1086/424666. View

11.

Tan E, Marcelin J, Virk A . Pre-travel counseling for immunocompromised travelers: A 12-year single-center retrospective review. Infect Dis Health. 2018; 24(1):13-22. DOI: 10.1016/j.idh.2018.09.083. View

12.

Schwartz B, Rosen J, Han P, Hynes N, Hagmann S, Rao S . Immunocompromised Travelers: Demographic Characteristics, Travel Destinations, and Pretravel Health Care from the U.S. Global TravEpiNet Consortium. Am J Trop Med Hyg. 2015; 93(5):1110-1116. PMC: 4703284. DOI: 10.4269/ajtmh.15-0185. View

13.

Bozio C, Isenhour C, McNamara L . Characteristics of and meningococcal disease prevention strategies for commercially insured persons receiving eculizumab in the United States. PLoS One. 2020; 15(11):e0241989. PMC: 7660549. DOI: 10.1371/journal.pone.0241989. View

14.

Nasim A, Anis S, Baqi S, Akhtar S, Baig-Ansari N . Clinical presentation and outcome of dengue viral infection in live-related renal transplant recipients in Karachi, Pakistan. Transpl Infect Dis. 2013; 15(5):516-25. DOI: 10.1111/tid.12114. View

15.

Mbaeyi S, Bozio C, Duffy J, Rubin L, Hariri S, Stephens D . Meningococcal Vaccination: Recommendations of the Advisory Committee on Immunization Practices, United States, 2020. MMWR Recomm Rep. 2021; 69(9):1-41. PMC: 7527029. DOI: 10.15585/mmwr.rr6909a1. View

16.

Overton E, Nurutdinova D, Sungkanuparph S, Seyfried W, Groger R, Powderly W . Predictors of immunity after hepatitis A vaccination in HIV-infected persons. J Viral Hepat. 2007; 14(3):189-93. DOI: 10.1111/j.1365-2893.2006.00822.x. View

17.

Crew P, Abara W, MCCulley L, Waldron P, Kirkcaldy R, Weston E . Disseminated Gonococcal Infections in Patients Receiving Eculizumab: A Case Series. Clin Infect Dis. 2018; 69(4):596-600. PMC: 6744347. DOI: 10.1093/cid/ciy958. View

18.

Bass A, Chakravarty E, Akl E, Bingham C, Calabrese L, Cappelli L . 2022 American College of Rheumatology Guideline for Vaccinations in Patients With Rheumatic and Musculoskeletal Diseases. Arthritis Rheumatol. 2023; 75(3):333-348. DOI: 10.1002/art.42386. View

19.

Talbot T, Comer J, Bloch K . Ehrlichia chaffeensis infections among HIV-infected patients in a human monocytic ehrlichiosis-endemic area. Emerg Infect Dis. 2003; 9(9):1123-7. PMC: 3016774. DOI: 10.3201/eid0909.020560. View

20.

Launay O, Grabar S, Gordien E, Desaint C, Jegou D, Abad S . Immunological efficacy of a three-dose schedule of hepatitis A vaccine in HIV-infected adults: HEPAVAC study. J Acquir Immune Defic Syndr. 2008; 49(3):272-5. DOI: 10.1097/QAI.0b013e318183a9c0. View